{"denomUnitsSelected":"Participants","description":"Blood biomarkers correlated with outcome to pembrolizumab or cetuximab, including T cell receptor (TCR) sequencing","reportingStatus":"NOT_POSTED","timeFrame":"Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months","title":"Correlative Analyses","type":"SECONDARY"}